GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial

Phase 3Positive

AI Analysis

Summary

GSK is advancing its mRNA-based seasonal flu vaccine candidate to Phase III trials, entering direct competition with Moderna shortly after Moderna received FDA approval for the first seasonal flu mRNA vaccine.

Clinical Trial Data

Phase

Phase III

Outcome Details

GSK advancing mRNA flu vaccine to Phase III trial

Importance:6/10

Sentiment:

0.50

mRNAinfluenzavaccineclinical trialPhase III

Related Companies

$GSK

Read the original article

Published by Clinical Trials Arena on September 1, 2026 2:12 PM

Read Original